Malaysia's drug regulator has given conditional approval for Chinese biopharmaceutical company Sinovac Biotech's (Nasdaq:SVA) COVID-19 vaccine to be used in young people aged between 12 and 17, Reuters news agency reported on Friday.
The health ministry stated that the drugs regulator had advised priority for Sinovac's vaccine among teenagers without co-morbidities or allergy problems, or otherwise deemed unsuitable for the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) vaccine.
Reportedly, teenagers younger than 18 in Malaysia started receiving COVID-19 doses last month, after vaccinations of more than 80% of adults were completed.
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment